Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which Alisertib cost permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. References 1. Meguid El, Nahas A, Bello AK. Chronic kidney disease: the global challenge. Lancet. 2005;365:331–440. 2. Levey AS, Schoolwerth AC, Burrows NR, Williams DE, Stith KR, McClellan W, et al. Comprehensive public health strategies for preventing the development, progression, and complications of CKD: report of an expert panel convened by the Centers for BYL719 research buy disease Control and Prevention. Am J Kidney Dis. 2009;53:522–35.PubMedCrossRef
3. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, et al. The definition, classification and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2010;80:17–28.PubMedCrossRef 4. Kiberd B. Screening for chronic kidney disease. BMJ. 2010;341:c5734.PubMedCrossRef 5. de Jong PE, van der Velde M, Gansevoort RT, Zoccali C. Screening for chronic kidney disease: where does Europe go?
Clin J Am Soc Nephrol. 2008;3:616–23.PubMedCrossRef 6. Collins AJ, Vassalotti JA, Wang C, Li S, Gilbertson DT, Liu J, et al. Who should be targeted for CKD screening? Impact of diabetes, hypertension, and cardiovascular disease. AR-13324 cost Am J Kidney Dis. 2009;53:S71–7.PubMedCrossRef 7. Chen N, Hsu CC, Yamagata K, Langham R. Challenging chronic kidney disease: experience from chronic kidney disease prevention programs in Shanghai, Japan, Taiwan and Australia. Nephrology (Carlton). 2010;15:31–6.CrossRef 8. Imai E, Yamagata K, Iseki K, Iso H, Horio M, Mkino H, et al. Kidney disease screening program in Japan: history, outcome, and perspectives. Clin J Am Soc Nephrol.
2007;2:1360–6.PubMedCrossRef 9. Kohro T, Furui Y, Mitsutake N, Fujii R, Morita H, Oku S, et al. The Japanese national health screening and intervention program aimed at ifenprodil preventing worsening of the metabolic syndrome. Int Heart J. 2008;49:193–203.PubMedCrossRef 10. Yamagata K, Iseki K, Nitta K, Imai H, Iino Y, Matsuo S, et al. Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin Exp Nephrol. 2008;12:1–8.PubMedCrossRef 11. Iseki K. Role of urinalysis in the diagnosis of chronic kidney disease (CKD). JMAJ. 2011;54:27–30. 12. Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA. 2003;290:3101–14.PubMedCrossRef 13. Ministry of Health, Labour and Welfare. Heisei 20 nendo tokutei kenko shinsatokutei hoken shidono jisshi jyokyo ni tsuite. Tokyo: Ministry of Health, Labour and Welfare; 2010. 14. Peralta CA, Shlipak MG, Judd S, Cushman M, McClellan W, Zakai NA, et al.